{"article":{"annotation":{"article_id":"brazil-anvisa-bans-irregular-medicines-october-2026","available_at":"2026-10-06T23:11:48.041355Z","geography_revision":"ef6ee0010dda5fe7b240fd514749b43e214c57da73222d2e40ec83b276dd0977","id":"9b4ec96012aa0c05605eea6f054fda9f375efca6fcac5c933ef48d5f1453c661","input_sha256":"45da2698cdfa8ef808029fa48b777229256690afeaa975a53200bd994e60f02e","limitations":["Rule-derived subjects are candidates, not verified editorial labels or calibrated model probabilities.","Coverage is distinct from event location. Unknown country/city/coordinates remain absent; no automatic geocoding.","Article geometries keep their stated precision and methodology; reproducing them is not independent coordinate verification."],"method":"controlled-rules-v1","places":[{"admin1":null,"city":null,"coordinate_note":null,"coordinate_reference_system":"OGC:CRS84","coordinate_source":null,"country":"BR","evidence":[{"field":"country","language":"en","note":"Explicit preserved editorial country/region; no city or national centroid inferred","source_urls":["https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"]}],"geometry":null,"id":"iso3166-1:BR","kind":"country-or-area","labels":{"ar":"البرازيل","en":"Brazil","es":"Brasil","fr":"Brésil"},"match_status":"candidate","precision":"regional","role":"coverage","uncertainty_m":null}],"rules_sha256":"d28c9c89703b56bd91fd887965d416d0115c2473d4bfbd3e558bcceafc3941dd","schema_version":1,"subjects":[{"concept_id":"medtop:07000000","confidence":null,"confidence_method":null,"evidence":[{"field":"category+topics","language":"en","note":"Preserved editorial category/topic; broad candidate only","source_urls":["https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"]}],"method":"controlled-rules-v1","rule_id":"health-broad","status":"candidate"}],"taxonomy_revision":"1f2db31d811fca07e99b16d402c10e2cc2965c9df1c7b41d9be348b40a24e7fb","taxonomy_version":"IPTC Media Topics 2026-Q2"},"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=fr","category":"health","content":{"key_points":[],"paragraphs":["L’autorité sanitaire brésilienne Anvisa a interdit la vente de plusieurs médicaments irréguliers le 6 octobre. Les mesures concernent une insuline glargine distribuée par une entreprise sans autorisation, un médicament composé commercialisé auprès du public sans ordonnance et des peptides non enregistrés.","Anvisa a également signalé le rappel volontaire par le fabricant d’un lot d’Imaavy et ordonné le rappel d’un lot de l’antibiotique Lizbi après avoir confirmé une perte de stérilité liée à un emballage endommagé. Cet article rend compte des mesures réglementaires et ne constitue pas un conseil médical individuel."],"sections":[]},"corrections":[{"at":"2026-10-07T00:55:00+03:00","language":"fr","text":"Des éditions allemande et portugaise, ainsi que les traductions des explications des données et des corrections, ont été ajoutées à cet article."}],"country":"BR","data":{"blocks":[{"columns":[{"key":"item","label":{"ar":"المنتج أو الفئة","de":"Produkt oder Kategorie","en":"Product or category","es":"Producto o categoría","fr":"Produit ou catégorie","pt":"Produto ou categoria","tr":"Ürün veya kategori"},"language":"en","type":"text"},{"key":"action","label":{"ar":"إجراء أنفيسا","de":"Maßnahme von Anvisa","en":"Anvisa action","es":"Medida de Anvisa","fr":"Mesure de l’Anvisa","pt":"Medida da Anvisa","tr":"Anvisa işlemi"},"language":"en","type":"text"}],"description":{"ar":"فئات المنتجات وأنواع الإجراءات في إعلان أنفيسا بتاريخ 6 أكتوبر 2026.","de":"Produkte und Maßnahmen in der Mitteilung von Anvisa vom 6. Oktober 2026.","en":"Products and action types in Anvisa’s October 6, 2026 notice.","es":"Productos y tipos de medidas del aviso de Anvisa del 6 de octubre de 2026.","fr":"Produits et types de mesures dans l’avis de l’Anvisa du 6 octobre 2026.","pt":"Produtos e tipos de medida no comunicado da Anvisa de 6 de outubro de 2026.","tr":"Anvisa’nın 6 Ekim 2026 duyurusundaki ürün grupları ve karar türleri."},"id":"brazil-anvisa-regulatory-actions","methodology":{"ar":"يلخص الجدول نطاق الإعلان وفق نص المصدر؛ ولا يقدم إرشاداً طبياً.","de":"Die Tabelle fasst den Umfang der Mitteilung mit den Begriffen der Quelle zusammen und enthält keine medizinische Beratung.","en":"The table summarizes the scope of the notice in the source’s terms; it does not provide medical guidance.","es":"La tabla resume el alcance del aviso según el texto fuente; no ofrece orientación médica.","fr":"Le tableau résume le champ de l’avis selon le texte source ; il ne fournit pas de conseil médical.","pt":"A tabela resume o escopo do comunicado nos termos da fonte; não fornece orientação médica.","tr":"Tablo karar kapsamını kaynak metindeki ifadelerle özetler; listelenen ilaçlar için tıbbi öneri içermez."},"rows":[{"action":"Sale of all lots prohibited; distributor lacked authorization.","item":"Insulin glargine 3 mL/100 IU, Costa Mar"},{"action":"Sale, distribution and advertising prohibited; regulator cited standardized non-individualized compounding marketed without prescription.","item":"Vermefree compounded medicine, Sintonia Pharma"},{"action":"Sale, manufacture, distribution, advertising, transport and use prohibited.","item":"Unregistered peptides listed in notice"},{"action":"Voluntary recall reported; possible glass particles in vials.","item":"Imaavy batch JNYJ1201"},{"action":"Recall ordered after confirmed sterility loss linked to compromised primary packaging.","item":"Lizbi batch 0000207107"}],"sourceUrls":["https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"],"title":{"ar":"الأدوية المحظورة أو المسحوبة","de":"Verbotene oder zurückgerufene Arzneimittel","en":"Medicines prohibited or recalled","es":"Medicamentos prohibidos o retirados","fr":"Médicaments interdits ou rappelés","pt":"Medicamentos proibidos ou recolhidos","tr":"Yasaklanan veya geri çağrılan ilaçlar"},"type":"table","updatedAt":"2026-10-07T00:55:00+03:00"}],"version":1},"data_downloads":[{"formats":{"csv":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026/data/brazil-anvisa-regulatory-actions?lang=fr&format=csv","json":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026/data/brazil-anvisa-regulatory-actions?lang=fr&format=json"},"id":"brazil-anvisa-regulatory-actions"}],"data_types":["table"],"editorial_illustration":{"alt":"Illustration conceptuelle de la santé publique, de la recherche et des données connectées.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"fr","scope":"topic","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"event_id":"event-8ff1924c-3faa-55d0-982f-f85ffe24522b","event_period":"2026-10-06","event_period_basis":"event-or-reference-period","id":"brazil-anvisa-bans-irregular-medicines-october-2026","image":null,"importance":0.6,"language":"fr","modified_at":"2026-10-07T00:55:00+03:00","publication_basis":"publication-record","published_at":"2026-10-06T17:11:49+00:00","reading_minutes":1,"region":"world","section_illustration":{"alt":"Illustration conceptuelle de la santé publique, de la recherche et des données connectées.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"fr","scope":"section","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"slug":"brazil-anvisa-bans-irregular-medicines-october-2026","sources":[{"checkedAt":"2026-10-06","name":"National Health Surveillance Agency of Brazil","publishedAt":"2026-10-06","url":"https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"}],"summary":"Les interdictions portent sur une insuline distribuée sans autorisation, un médicament composé irrégulièrement et des peptides non enregistrés, ainsi que deux lots présentant des problèmes de qualité.","text":"Les interdictions portent sur une insuline distribuée sans autorisation, un médicament composé irrégulièrement et des peptides non enregistrés, ainsi que deux lots présentant des problèmes de qualité.\n\nL’autorité sanitaire brésilienne Anvisa a interdit la vente de plusieurs médicaments irréguliers le 6 octobre. Les mesures concernent une insuline glargine distribuée par une entreprise sans autorisation, un médicament composé commercialisé auprès du public sans ordonnance et des peptides non enregistrés.\n\nAnvisa a également signalé le rappel volontaire par le fabricant d’un lot d’Imaavy et ordonné le rappel d’un lot de l’antibiotique Lizbi après avoir confirmé une perte de stérilité liée à un emballage endommagé. Cet article rend compte des mesures réglementaires et ne constitue pas un conseil médical individuel.\n\nDes éditions allemande et portugaise, ainsi que les traductions des explications des données et des corrections, ont été ajoutées à cet article.","title":"L’Anvisa interdit la vente de médicaments irréguliers au Brésil","topics":[],"translations":[{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=tr","language":"tr","url":"https://newsverum.com/tr/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=en","language":"en","url":"https://newsverum.com/en/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=ar","language":"ar","url":"https://newsverum.com/ar/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=fr","language":"fr","url":"https://newsverum.com/fr/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=es","language":"es","url":"https://newsverum.com/es/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=de","language":"de","url":"https://newsverum.com/de/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=pt","language":"pt","url":"https://newsverum.com/pt/news/brazil-anvisa-bans-irregular-medicines-october-2026"}],"url":"https://newsverum.com/fr/news/brazil-anvisa-bans-irregular-medicines-october-2026"},"version":"1"}